Showing 4731-4740 of 8483 results for "".
- FixMySkin Unveils New Lookhttps://practicaldermatology.com/news/fixmyskin-unveils-new-look/2458974/FixMySkin Healing Balms with 1% Hydrocortisone have a new look with the same great formula. Now available in environmentally friendly packaging, these balms come in two convenient sizes for the lips and body. Th
- Promius Pharma Launches Zenatane 30mg Dosehttps://practicaldermatology.com/news/promius-pharma-launches-zenatane-30mg-dose/2458977/Promius Pharma, LLC has announced that ZENATANE™(Isotretinoin Capsules USP) are now available in a 30mg dose. Zenatane, AB rated equivalent to Accutane 30mg, has been introduced in response to dermatologists who have continued to request this strength of the drug. <
- NeoStrata® Launches SKIN ACTIVE Dermal Replenishmenthttps://practicaldermatology.com/news/neostrata-launches-skin-active-dermal-replenishment/2458980/NeoStrata Company, Inc., today announced the launch of SKIN ACTIVE Dermal Replenishment, an intense hydrator that delivers a powerful four-pronged anti-aging approach. Created to synergistically replenish optimal hydration levels and reverse signs of a
- Nanotechnology Study Offers New Direction for Wound Healing Therapyhttps://practicaldermatology.com/news/nanotechnology-study-offers-new-direction-for-wound-healing-therapy/2458991/A novel nanoparticle technology appears to promote wound healing and has led researchers to a new therapeutic target for wound healing, a new study says. Writing in Journal of Investigat
- Merz Announces Availability of Radiesse® (+) with Integral 0.3% Lidocainehttps://practicaldermatology.com/news/merz-announces-availability-of-radiesse-with-integral-03-lidocaine/2458992/Radiesse® (+) with integral 0.3% Lidocaine (Radiesse® Plus) from Merz North America, US affiliate of the global Merz Pharma Group, has received FDA approval and is now available to US physicians. Radiesse® (+) provides the immediate lift of wrinkles an
- Promius Pharma, LLC to Market, Distribute Trianex 0.05%https://practicaldermatology.com/news/promius-pharma-llc-to-market-distribute-trianex-005/2458997/Promius Pharma, LLC, has acquired the rights to market and distribute Trianex® 0.05% (Triamcinolone Acetonide Ointment, USP) in the United States from CMP Pharma, Inc. Trianex Ointment, a mid-potency corticosteroid, is notable for its white formulation that has the look and feel of
- Cipher Pharmaceuticals appoints Lynne Bulger as Vice President, Medical Affairshttps://practicaldermatology.com/news/cipher-pharmaceuticals-appoints-lynne-bulger-as-vice-president-medical-affairs/2459022/Cipher Pharmaceuticals Inc. appointed Lynne Bulger as Vice President, Medical and Clinical Affairs to lead the Company's clinical development and medical affairs efforts for current and new pipeline products. Ms. Bulger has 27 years of experience in drug development in the pharmaceuti
- ASDSA Names 2014 Patient Safety Hero Award Winnershttps://practicaldermatology.com/news/asdsa-named-2014-patient-safety-hero-award-winners/2459025/Honoring physicians and dermatologic societies whose notable efforts for greater patient safety in cosmetic procedures have made a difference last year, the American Society for Dermatologic Surgery Association (ASDSA) recently named the 2014 winners of its an
- Oculus Innovative Sciences Launches IntraDerm Pharmaceuticals, New Dermatology Divisionhttps://practicaldermatology.com/news/oculus-innovative-sciences-launches-intraderm-pharmaceuticals-new-dermatology-division/2459028/Oculus Innovative Sciences, Inc., a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, has launched a
- FDA Grants Soligenix Fast Track Designation for SGX301 for First-Line Treatment of Cutaneous T-Cell Lymphomahttps://practicaldermatology.com/news/fda-grants-soligenix-fast-track-designation-for-sgx301-for-first-line-treatment-of-cutaneous-t-cell-lymphoma/2459030/Soligenix, Inc.’s SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) received "fast track" designation from the FDA. Fast track is a designation that the FDA reserves for a drug intended to treat a serious or life-thre